Healthcare Services company Thyrocare Technologies announced Q3FY26 results Consolidated revenue registered a 18% YoY growth, driven primarily by a 20% increase in the Pathology segment. In the Pathology business, franchise revenue grew by 12% YoY, while partnership revenue including pharmeasy business recorded a robust 39% YoY growth. Thyrocare, India’s largest diagnostic test volume processor, processed 49.6 million tests in Q3FY26, marking a strong 22% YoY growth and reinforcing its leadership position in the diagnostics industry. Consolidated EBITDA grew by 38% YoY, and Profit After Tax (PAT) grew by 47% YoY to Rs 27.91 crore after considering exceptional items relating to non-recurring labour code & bonus issue impact. Achieved Six Sigma quality standards (defined as 3.4 CPMT), reducing complaints per million tests to 3.2 (down 43% YoY) with ATAT at 3.28 hours - India's first diagnostic chain to hit this benchmark. Rahul Guha, MD & CEO, Thyrocare Technologies, said: “We are pleased to report a robust set of results for the quarter. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India.” Result PDF